An Innovative Mobile Health Intervention to Improve Self-care in Patients With Heart Failure
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04262544 |
Recruitment Status :
Completed
First Posted : February 10, 2020
Last Update Posted : April 28, 2023
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Heart Failure | Behavioral: iCardia4HF Other: Usual Care | Not Applicable |
More than 6.5 million people have heart failure (HF) in the United States and 960,000 new cases are reported annually. HF is associated with high mortality and hospitalization rates, high costs, and poor health-related quality of life (HRQL). Despite major improvements in outcomes with medical and surgical therapy, admission rates following a HF-related hospitalization remain high with 25% of patients readmitted to the hospital within 30-days and up to 50% readmitted within 6 months. Previous research shows that adherence to routine HF self-care behaviors reduces the risk of all-cause mortality and HF-related hospitalization, and improves HRQL. However, self-care has generally been found to be poor among HF patients, particularly minority populations. Nonadherence to HF symptom monitoring and medication use is remarkably high even among recently discharged patients hospitalized due to a HF exacerbation. Recent advances in consumer-based mobile health (mHealth) technologies, such as smartphones, mobile health apps, wearable sensors, and other smart and connected health devices, offer scalable and affordable solutions for promoting better HF self-care and expanding delivery of care services to communities that are difficult to reach. However, no prior studies have assessed the impact of these technologies on HF self-care and patient outcomes.
This study aims to conduct a pilot randomized controlled trial (RCT) of a patient-centered intervention named iCardia4HF that promotes adherence to HF self-care through the use of commercial mHealth devices and app tools. iCardia4HF consists of: (1) a patient-centered mHealth app, developed in partnership with the Heart Failure Society of America, that interfaces with multiple connected health devices and comprises a number of self- monitoring, patient education, and adherence reminder tools for improving self-care; and (2) individually tailored text-messages (TMs) targeting health beliefs, self-care efficacy, and HF-knowledge. Study participants (n=92) diagnosed with HF will be randomly assigned to iCardia4HF or the control group for 12 weeks. Specific aims are to: 1) assess the feasibility and acceptance of iCardia4HF; 2) examine the preliminary efficacy of iCardia4HF on objectively assessed measures of HF self-care using real- time data from the connected health devices and app, as well as self-reported Self-Care and HRQL; track the number of hospitalizations and emergency room (ER) visits over 12 weeks; and 3) examine the mediating effect of intervention target variables (health beliefs, self-care efficacy, and HF-knowledge) and impact of independent patient factors on HF self-care.
This study represents an important step in identifying an affordable and scalable mHealth intervention that has the potential to bring about a new paradigm in self-care management of HF.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 89 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Care Provider, Outcomes Assessor) |
Masking Description: | Care providers (doctors and nurses) providing usual care to study participants will be blinded to the allocation of participants. Data collectors and assessors of subjective outcomes (e.g. health beliefs, self-efficacy, self-care) will be blinded to the allocation. Study participants will be asked not to reveal to their provider and assessor which group they are assigned to. Data collectors/assessors will have restricted access to patient data in REDCap and will not share the same space with other study investigators. |
Primary Purpose: | Treatment |
Official Title: | An Innovative Mobile Health Intervention to Improve Self-care in Patients With Heart Failure |
Actual Study Start Date : | February 20, 2020 |
Actual Primary Completion Date : | September 30, 2022 |
Actual Study Completion Date : | December 31, 2022 |
Arm | Intervention/treatment |
---|---|
Experimental: mHealth
Intervention group
|
Behavioral: iCardia4HF
Participants in the intervention group will receive the following main components in addition to usual care: 1) the Heart Failure Health Storylines mobile app which supports daily self-monitoring and management of vital signs and symptoms; 2) three connected health devices (Fitbit activity tracker, Withings Cardio Body weight scale and blood pressure monitor), and 3) a program of tailored text-messages targeting health beliefs, self-efficacy, and HF-knowledge. |
Active Comparator: Usual Care
Control group
|
Other: Usual Care
Participants assigned to the control group will receive usual care and the same connected health devices (Fitbit activity tracker, Withings weight scale and blood pressure monitor) as patients in the intervention group, but without the heart failure health storylines mobile app and text-messaging program. Usual care includes patient education before hospital discharge, and follow-up visits at the outpatient HF clinic a week after discharge and monthly thereafter depending on the patient's condition. Patient education includes literacy-sensitive, education material about HF self-care developed by the Sheps Center for Health Services Research,and a 40-minute education session with an APN and a dietician to review and discuss the education material provided to the patient. |
- Medication adherence (dose count) [ Time Frame: Weeks 1 to 12 ]Percent of prescribed number of doses taken
- Medication adherence (dose time) [ Time Frame: Weeks 1 to 12 ]Percent of doses taken on schedule within 25% of the expected time interval
- Adherence to daily self-monitoring of weight [ Time Frame: Weeks 1 to 12 ]Number of days patients completed at least one measurement between 12 am and 11:59pm
- Adherence to daily self-monitoring of blood pressure [ Time Frame: Weeks 1 to 12 ]Number of days patients completed at least one BP measurement between 12 am and 11:59pm
- Adherence to self-monitoring of HF symptoms [ Time Frame: Weeks 1 to 12 ]Number of days intervention patients used the mobile app to record their HF symptoms
- Physical activity - Steps [ Time Frame: Weeks 1 to 12 ]Number of daily steps (measured with a Fitbit device)
- Moderate-to-Vigorous Physical Activity [ Time Frame: Weeks 1 to 12 ]Number of moderate-to-vigorous physical activity minutes per day (measured with a Fitbit device)
- Adherence to low-sodium diet [ Time Frame: Baseline, 12 Weeks ]Sodium intake will be assessed with a urinary sample test
- Self-reported Self-care [ Time Frame: Baseline, 30 days, and 12 Weeks ]Measured with the Self-Care Heart Failure Index (SCHFI) v.7.2. Each scale score ranges from 0 to 100. Higher scores indicate better self-care.
- Health Beliefs about Medication Compliance [ Time Frame: Baseline, 30 days, and 12 Weeks ]Beliefs about Medication Compliance Scale (12-items)
- Health Beliefs about Dietary Compliance [ Time Frame: Baseline, 30 days, and 12 Weeks ]Beliefs about Dietary Compliance Scale (12 items)
- Health Beliefs about Self-Monitoring Compliance [ Time Frame: Baseline, 30 days, and 12 Weeks ]Beliefs about Self-Monitoring Scale (18 items)
- HF-knowledge [ Time Frame: Baseline, 30 days, and 12 Weeks ]HF-specific knowledge will be assessed with the Dutch Heart Failure Knowledge Scale (DHFK), a 15-item questionnaire measuring general knowledge about HF, symptom recognition, and treatment (e.g. diet and fluid restriction)
- Health-related Quality of life (HRQoL) [ Time Frame: Baseline, 30 days, and 12 Weeks ]HRQoL will be measured with the Kansas City Cardiomyopathy Questionnaire, which contains 23-items that can be quantified into five subscales: physical limitations, symptoms (frequency, severity, and change over time), quality of life (QoL), social interference, and self-efficacy. Lower scores indicate worse HRQoL.
- HF-related hospitalizations [ Time Frame: Weeks 1 to 12 ]Number of patients with an event
- HF-related hospitalization rate [ Time Frame: Weeks 1 to 12 ]Number of hospitalizations per person
- All-cause hospitalizations [ Time Frame: Weeks 1 to 12 ]Number of patients with an event
- All-cause hospitalization rate [ Time Frame: Weeks 1 to 12 ]Number of all-cause hospitalizations per person
- Emergency room visits [ Time Frame: Weeks 1 to 12 ]Number of patients with an event
- Emergency room visit rate [ Time Frame: Weeks 1 to 12 ]Number of emergency room visits per person
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Chronic HF, Stage C
- ≥ 18 years of age
- Being treated with oral diuretics for heart failure
- Suboptimal HF self-care adherence (score 1 or 2 in at least two items of the Self-care of Heart Failure Index v.7.2)
- Ability to speak and read English
Exclusion Criteria:
- Planned coronary revascularization, Transcatheter Aortic Valve Implantation (TAVI), Cardiac Resynchronization Therapy (CRT) - implantation, and/or heart transplantation (HTx) within the next 3 months.
- Coronary revascularization and/or CRT-implantation within the last 30 days
- Advanced renal disease (stage IV CKD, GFR<30, or hemodialysis)
- Known alcohol or drug use
- End-stage HF (hospice candidate)
- Active cancer
- Pregnancy
- Not able to take care of self (eat, dress, walk, bath, take medications, or use the toilet)
- Discharged to or already living in a nursing home or other care facility other than home
- Cognitive impairment (MoCA score < 22).
- Prior use of study devices for self-care or participation in a similar trial
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04262544
United States, Illinois | |
University of Illinois Hospital & Health Sciences System | |
Chicago, Illinois, United States, 60612 |
Principal Investigator: | Spyros Kitsiou | University of Illinois at Chicago |
Responsible Party: | Spyros Kitsiou, Assistant Professor, University of Illinois at Chicago |
ClinicalTrials.gov Identifier: | NCT04262544 |
Other Study ID Numbers: |
2019-0790 1R21NR018281-01A1 ( U.S. NIH Grant/Contract ) |
First Posted: | February 10, 2020 Key Record Dates |
Last Update Posted: | April 28, 2023 |
Last Verified: | April 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Final research data along with metadata and descriptors will be shared to make sharing meaningful and usable by other researchers. More specifically, we will share both de-identified individual-level data and aggregate data in the form of summary statistics and tables. For the individual-level data, we will develop a data dictionary and documentation guide to maximize the utility of the data and to help qualified researchers understand and properly use the data as needed. |
Supporting Materials: |
Study Protocol Clinical Study Report (CSR) |
Time Frame: | Within 2 years after the final data collection is completed or within one year after the publication of the main outcomes manuscript (whichever comes first), we will share the final, completely de-identified dataset with the research community. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
mHealth text messaging smartphone mobile apps |
wearables heart failure self-management telehealth |
Heart Failure Heart Diseases Cardiovascular Diseases |